Large Scale Flows from Orion-South

Multiple optical outflows are known to exist in the vicinity of the active star formation region called Orion-South (Orion-S). We have mapped the velocity of low ionization features in the brightest part of the Orion Nebula, including Orion-S, and imaged the entire nebula with the Hubble Space Telescope. These new data, combined with recent high resolution radio maps of outflows from the Orion-S region, allow us to trace the origin of the optical outflows. It is confirmed that HH 625 arises from the blueshifted lobe of the CO outflow from 136-359 in Orion-S while it is likely that HH 507 arises from the blueshifted lobe of the SiO outflow from the nearby source 135-356. It is likely that redshifted lobes are deflected within the photon dominated region behind the optical nebula. This leads to a possible identification of a new large shock to the southwest from Orion-S as being driven by the redshifted CO outflow arising from 137-408. The distant object HH 400 is seen to have two even further components and these all are probably linked to either HH 203, HH 204, or HH 528. Distant shocks on the west side of the nebula may be related to HH 269. The sources of multiple bright blueshifted Herbig-Haro objects (HH 202, HH 203, HH 204, HH 269, HH 528) remain unidentified, in spite of earlier claimed identifications. Some of this lack of identification may arise from the fact that deflection in radial velocity can also produce a change in direction in the plane of the sky. The best way to resolve this open question is through improved tangential velocities of low ionization features arising where the outflows first break out into the ionized nebula.Comment: Astronomical Journal, in press. Some figures are shown at reduced resolution. A full-resolution version is available at http://ifront.org/wiki/Orion_South_Outflows_Pape

Correction to: Aphid and caterpillar feeding drive similar patterns of induced defences and resistance to subsequent herbivory in wild cotton

Correction to: Planta (2023) 258:113 https://doi.org/10.1007/s00425-023-04266-1Peer reviewe

Radio Measurements of the stellar proper motions in the core of the Orion Nebula Cluster

Sergio A. Dzib, et al, 'RADIO MEASUREMENTS OF THE STELLAR PROPER MOTIONS IN THE CORE OF THE ORION NEBULA CLUSTER', The Astrophysical Journal, Vol. 834(2), 10 pp, January 2017. doi:10.3847/1538-4357/834/2/139 © 2017. The American Astronomical Society. All rights reserved.Using multi-epoch VLA observations, covering a time baseline of 29.1 years, we have measured the proper motions of 88 young stars with compact radio emission in the core of the Orion Nebula Cluster (ONC) and the neighboring BN/KL region. Our work increases the number of young stars with measured proper motion at radio frequencies by a factor of 2.5 and enables us to perform a better statistical analysis of the kinematics of the region than was previously possible. Most stars (79 out of 88) have proper motions consistent with a Gaussian distribution centered on $\overline{\mu_{\alpha}\cos{\delta}}=1.07\pm0.09\quad{\rm mas\,yr^{-1}}$, and $\overline{\mu_{\delta}}=-0.84\pm0.16\quad{\rm mas\,yr^{-1}}$, with velocity dispersions of $\sigma_{\alpha}=1.08\pm0.07\quad{\rm mas\,\,yr^{-1}},$ $\sigma_{\delta}=1.27\pm0.15\quad{\rm mas\,\,yr^{-1}}$. We looked for organized movements of these stars but found no clear indication of radial expansion/contraction or rotation. The remaining nine stars in our sample show peculiar proper motions that differ from the mean proper motions of the ONC by more than 3-$\sigma$. One of these stars, V 1326 Ori, could have been expelled from the Orion Trapezium 7,000 years ago. Two could be related to the multi-stellar disintegration in the BN/KL region, in addition to the previously known sources BN, I and n. The others either have high uncertainties (so their anomalous proper motions are not firmly established) or could be foreground objects.Peer reviewedFinal Published versio

Optimization of Pathogenicity Tests for Selection of Native Isolates of Entomopathogenic Fungi Isolated from Citrusgrowing Areas of México on Adults ofDiaphorina citriKuwayama (Hemiptera: Liviidae)

Huanglonbing (HLB), es considerado una de las más letales enfermedades de los cítricos alrededor del mundo, y ha alcanzado las principales áreas de producción de limón Mexicano (Citrus latifolia Tanaka) en la costa del pacifico de México. Los productores han iniciado el uso de insecticidas para controlar las poblaciones del psílido asiático de los cítricos, Diaphorina citri Kuwayama (Hemiptera: Liviidae), el vector del patógeno ‘Candidatus Liberibacter asiaticus’ asociado con el HLB. Actualmente los costos de los insecticidas y los efectos secundarios de su uso son las principales preocupaciones, ya que podrían perjudicar la estrategia de manejo contra el vector; y por lo tanto, alternativas ecológicas y económicamente viables a los insecticidas convencionales serian necesarias a corto plazo. Por tanto, el objetivo de este estudio fue evaluar la patogenicidad de 27 aislados nativos y 3 cepas de hongos entomopatógenos para determinar su potencial como agentes de control biológico sobre Diaphorina citri usando 2 diferentes métodos de bioensayo. Los bioensayos fueron realizados bajo condiciones de laboratorio (26 ± 2 °C, 60 ± 5% H.R y 16:8 h L:O) mediante la exposición de insectos adultos a una concentración de 1 × 108 conidios por mililitro utilizando 2 diferentes métodos de aplicación, es decir, por asperjado de esporas en las plántulas de cítricos y por asperjado directo a los psílidos adultos. Los resultados mostraron que para el asperjado directo a los adultos los aislados HIB-24 (B. bassiana) y HIB-32 (I. fumosorosea) mostraron el mayor porcentaje de mortalidad (60.66%). Respecto al asperjado de plántulas el aislado HIB-19 (I. fumosorosea) mostró el mayor porcentaje de mortalidad (62.02%). Los resultados de este estudio demuestran el potencial para el uso de hongos entomopatógenos en el manejo de D. citri en México. ABSTRACT Huanglongbing (HLB), considered one of the most lethal diseases of citrus worldwide, has reached the main areas of Mexican lime (Citrus latifolia Tanaka) fruit production on the Pacific coast of México. Growers have initiated intensive use of insecticides in order to control populations of the Asian citrus psyllid, Diaphorina citri Kuwayama (Hemiptera: Liviidae), the vector of the pathogen, ‘Candidatus Liberibacter asiaticus’ associated with huanglongbing. Presently, costs of insecticides and the side effects of their use are major concerns, because they could impair the management strategy against the vector; and thus, ecologically and economically viable alternatives to conventional insecticides are required in the short term. Therefore the goal of this study was to evaluate the pathogenicity of 27 native isolates and 3 strains of entomopathogenic fungi and determine their potential as biological control agents of D. citri by using 2 different bioassay methods. Bioassays were performed under laboratory conditions (26 ± 2 °C, 60 ± 5% RH and 16:8 h L:D) by exposing adult insects to a concentration of 1 × 108 conidia per milliliter using 2 different application methods, i.e., spraying the spores onto the citrus seedlings and spraying the spores directly onto the adult psyllids. The results showed that by direct spraying the adults, HIB-24 (B. bassiana) and HIB-32 (I. fumosorosea) isolates showed the highest mortality (60.66%). Regarding spraying of the seedlings, HIB-19 (I. fumosorosea) showed the highest percentage of mortality (62.02%). The results from this study demonstrate potential for using entomopathogenic fungi in the management of D. citri in México

Bladder cancer index: cross-cultural adaptation into Spanish and psychometric evaluation

BACKGROUND: The Bladder Cancer Index (BCI) is so far the only instrument applicable across all bladder cancer patients, independent of tumor infiltration or treatment applied. We developed a Spanish version of the BCI, and assessed its acceptability and metric properties. METHODS: For the adaptation into Spanish we used the forward and back-translation method, expert panels, and cognitive debriefing patient interviews. For the assessment of metric properties we used data from 197 bladder cancer patients from a multi-center prospective study. The Spanish BCI and the SF-36 Health Survey were self-administered before and 12 months after treatment. Reliability was estimated by Cronbach's alpha. Construct validity was assessed through the multi-trait multi-method matrix. The magnitude of change was quantified by effect sizes to assess responsiveness. RESULTS: Reliability coefficients ranged 0.75-0.97. The validity analysis confirmed moderate associations between the BCI function and bother subscales for urinary (r = 0.61) and bowel (r = 0.53) domains; conceptual independence among all BCI domains (r ≤ 0.3); and low correlation coefficients with the SF-36 scores, ranging 0.14-0.48. Among patients reporting global improvement at follow-up, pre-post treatment changes were statistically significant for the urinary domain and urinary bother subscale, with effect sizes of 0.38 and 0.53. CONCLUSIONS: The Spanish BCI is well accepted, reliable, valid, responsive, and similar in performance compared to the original instrument. These findings support its use, both in Spanish and international studies, as a valuable and comprehensive tool for assessing quality of life across a wide range of bladder cancer patients

Assessing Outcomes of Patients Subject to Intensive Care to Facilitate Organ Donation: A Spanish Multicenter Prospective Study

Intensive Care to facilitate Organ Donation (ICOD) consists of the initiation or continuation of intensive care measures in patients with a devastating brain injury (DBI) in whom curative treatment is deemed futile and death by neurological criteria (DNC) is foreseen, to incorporate organ donation into their end-of-life plans. In this study we evaluate the outcomes of patients subject to ICOD and identify radiological and clinical factors associated with progression to DNC. In this first prospective multicenter study we tested by multivariate regression the association of clinical and radiological severity features with progression to DNC. Of the 194 patients, 144 (74.2%) patients fulfilled DNC after a median of 25 h (95% IQR: 17–44) from ICOD onset. Two patients (1%) shifted from ICOD to curative treatment, both were alive at discharge. Factors associated with progression to DNC included: age below 70 years, clinical score consistent with severe brain injury, instability, intracranial hemorrhage, midline shift ≥5 mm and certain types of brain herniation. Overall 151 (77.8%) patients progressed to organ donation. Based on these results, we conclude that ICOD is a beneficial and efficient practice that can contribute to the pool of deceased donors

Guía de práctica clínica para la prevención, diagnóstico, tratamiento y rehabilitación de la falla cardiaca en población mayor de 18 años, clasificación B, C y D

La falla cardíaca es un síndrome clínico caracterizado por síntomas y signos típicos de insuficiencia cardíaca, adicional a la evidencia objetiva de una anomalía estructural o funcional del corazón. Guía completa 2016. Guía No. 53Población mayor de 18 añosN/

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Global Retinoblastoma Presentation and Analysis by National Income Level.

Importance: Early diagnosis of retinoblastoma, the most common intraocular cancer, can save both a child's life and vision. However, anecdotal evidence suggests that many children across the world are diagnosed late. To our knowledge, the clinical presentation of retinoblastoma has never been assessed on a global scale. Objectives: To report the retinoblastoma stage at diagnosis in patients across the world during a single year, to investigate associations between clinical variables and national income level, and to investigate risk factors for advanced disease at diagnosis. Design, Setting, and Participants: A total of 278 retinoblastoma treatment centers were recruited from June 2017 through December 2018 to participate in a cross-sectional analysis of treatment-naive patients with retinoblastoma who were diagnosed in 2017. Main Outcomes and Measures: Age at presentation, proportion of familial history of retinoblastoma, and tumor stage and metastasis. Results: The cohort included 4351 new patients from 153 countries; the median age at diagnosis was 30.5 (interquartile range, 18.3-45.9) months, and 1976 patients (45.4%) were female. Most patients (n = 3685 [84.7%]) were from low- and middle-income countries (LMICs). Globally, the most common indication for referral was leukocoria (n = 2638 [62.8%]), followed by strabismus (n = 429 [10.2%]) and proptosis (n = 309 [7.4%]). Patients from high-income countries (HICs) were diagnosed at a median age of 14.1 months, with 656 of 666 (98.5%) patients having intraocular retinoblastoma and 2 (0.3%) having metastasis. Patients from low-income countries were diagnosed at a median age of 30.5 months, with 256 of 521 (49.1%) having extraocular retinoblastoma and 94 of 498 (18.9%) having metastasis. Lower national income level was associated with older presentation age, higher proportion of locally advanced disease and distant metastasis, and smaller proportion of familial history of retinoblastoma. Advanced disease at diagnosis was more common in LMICs even after adjusting for age (odds ratio for low-income countries vs upper-middle-income countries and HICs, 17.92 [95% CI, 12.94-24.80], and for lower-middle-income countries vs upper-middle-income countries and HICs, 5.74 [95% CI, 4.30-7.68]). Conclusions and Relevance: This study is estimated to have included more than half of all new retinoblastoma cases worldwide in 2017. Children from LMICs, where the main global retinoblastoma burden lies, presented at an older age with more advanced disease and demonstrated a smaller proportion of familial history of retinoblastoma, likely because many do not reach a childbearing age. Given that retinoblastoma is curable, these data are concerning and mandate intervention at national and international levels. Further studies are needed to investigate factors, other than age at presentation, that may be associated with advanced disease in LMICs